Fiduciary Group LLC lessened its position in shares of Eli Lilly And Co (NYSE:LLY) by 4.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,888 shares of the company’s stock after selling 423 shares during the period. Fiduciary Group LLC’s holdings in Eli Lilly And Co were worth $1,095,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Bessemer Group Inc. lifted its stake in shares of Eli Lilly And Co by 2,354.5% during the second quarter. Bessemer Group Inc. now owns 569,510 shares of the company’s stock worth $63,096,000 after purchasing an additional 546,307 shares in the last quarter. Janney Capital Management LLC acquired a new position in shares of Eli Lilly And Co during the first quarter worth about $246,000. Thoroughbred Financial Services LLC lifted its stake in shares of Eli Lilly And Co by 1.4% during the first quarter. Thoroughbred Financial Services LLC now owns 7,612 shares of the company’s stock worth $988,000 after purchasing an additional 105 shares in the last quarter. Smithfield Trust Co. lifted its stake in shares of Eli Lilly And Co by 1.6% during the first quarter. Smithfield Trust Co. now owns 7,277 shares of the company’s stock worth $944,000 after purchasing an additional 114 shares in the last quarter. Finally, Advisor Group Inc. lifted its stake in shares of Eli Lilly And Co by 0.9% during the first quarter. Advisor Group Inc. now owns 66,256 shares of the company’s stock worth $8,601,000 after purchasing an additional 567 shares in the last quarter. 78.92% of the stock is owned by hedge funds and other institutional investors.
Several research firms recently commented on LLY. TheStreet cut Eli Lilly And Co from a “b+” rating to a “c+” rating in a research note on Thursday, May 9th. BMO Capital Markets boosted their price target on Eli Lilly And Co from $130.00 to $133.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. Zacks Investment Research cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Tuesday, May 21st. Edward Jones upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price target on the stock in a research note on Tuesday, April 23rd. Finally, ValuEngine cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, June 28th. Nine equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $123.49.
In other news, VP Michael J. Harrington sold 16,000 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the completion of the transaction, the vice president now directly owns 110,300 shares of the company’s stock, valued at $12,874,216. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Joshua L. Smiley bought 426 shares of the stock in a transaction dated Wednesday, June 5th. The shares were bought at an average cost of $118.03 per share, with a total value of $50,280.78. Following the completion of the acquisition, the chief financial officer now directly owns 30,410 shares of the company’s stock, valued at approximately $3,589,292.30. The disclosure for this purchase can be found here. 0.11% of the stock is owned by insiders.
Eli Lilly And Co stock traded up $1.53 during midday trading on Monday, hitting $112.05. The stock had a trading volume of 27,254 shares, compared to its average volume of 4,237,085. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 4.98. The stock has a market cap of $106.42 billion, a P/E ratio of 20.15, a P/E/G ratio of 1.95 and a beta of 0.19. Eli Lilly And Co has a 12 month low of $103.65 and a 12 month high of $132.13. The business has a fifty day moving average price of $110.59 and a 200 day moving average price of $118.03.
Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.45 by $0.05. The firm had revenue of $5.64 billion during the quarter, compared to analyst estimates of $5.59 billion. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. Eli Lilly And Co’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the previous year, the company earned $1.48 earnings per share. On average, equities analysts anticipate that Eli Lilly And Co will post 5.72 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a $0.645 dividend. This represents a $2.58 annualized dividend and a yield of 2.30%. The ex-dividend date is Wednesday, August 14th. Eli Lilly And Co’s dividend payout ratio is currently 46.49%.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Why is momentum important to successful trading?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.